低血红蛋白与早期类风湿关节炎影像学损伤进展:III期试验二次分析
该研究对PREMIER试验中接受阿达木单抗、甲氨蝶呤或联合治疗2年的早期类风湿关节炎患者进行事后分析,发现基线血红蛋白与改良Sharp/van der Heijde评分变化(ΔSHS)呈负相关,贫血可预测甲氨蝶呤治疗患者104周内及阿达木单抗和联合治疗患者26周内更大的ΔSHS,且低血红蛋白对关节损伤进展的影响独立于DAS28-CRP。
要点
- 基线血红蛋白与ΔSHS呈负相关,调整分析中男女均P<0.05。
- 基线贫血预测甲氨蝶呤治疗患者104周内更大的ΔSHS。
- 低血红蛋白对关节损伤进展的影响独立于DAS28-CRP。
核心结论
- 低血红蛋白是甲氨蝶呤治疗的早期类风湿关节炎患者影像学关节损伤进展的DAS28-CRP独立预测因素。
研究设计与样本
- PREMIER试验的事后分析,纳入接受阿达木单抗、甲氨蝶呤或联合治疗2年的早期类风湿关节炎患者。
主要发现
- 基线血红蛋白与ΔSHS在调整分析中呈负相关,男女均P<0.05。
- 基线贫血预测甲氨蝶呤治疗患者104周内更大的ΔSHS,以及阿达木单抗和联合治疗患者26周内更大的ΔSHS。
- 随时间降低的血红蛋白浓度及贫血时间与更大的损伤进展相关(P<0.001)。
- 低血红蛋白对关节损伤进展的影响在达到低疾病活动度的患者中仍显著。
- 低血红蛋白对关节损伤进展的影响在阿达木单抗和联合治疗患者中随时间减弱,在临床应答者中亦减弱。
关键数值与推荐
- 低疾病活动度定义为DAS28-CRP评分<3.2。
- 临床应答采用美国风湿病学会20%改善标准于第24周评估。
- 贫血采用世界卫生组织性别特异性标准定义。
- 关节损伤进展采用改良总Sharp/van der Heijde评分变化(ΔSHS)测量。
临床怎么用
- 在早期类风湿关节炎甲氨蝶呤治疗患者中,低血红蛋白可提示影像学关节损伤进展风险较高。
- 低血红蛋白对关节损伤进展的预测价值独立于DAS28-CRP,可辅助风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study low blood hemoglobin concentrations as a predictor of radiographic damage progression in patients with rheumatoid arthritis (RA). METHODS: Post hoc analyses were performed in patients from the PREMIER trial with early RA undergoing 2 years of adalimumab (ADA), methotrexate (MTX), or ADA + MTX combination therapy. Low disease activity was defined as a score <3.2 on the 28-joint Disease Activity Score using the C-reactive protein level (DAS28-CRP), and clinical response by the American College of Rheumatology criteria for 20% improvement at week 24. Baseline or mean hemoglobin concentrations over time, or anemia as defined using sex-specific World Health Organization criteria, were analyzed in mixed-effects models for longitudinal data in men and women as predictors of progressive joint damage, as measured by the modified total Sharp/van der Heijde score (ΔSHS). Data were adjusted for treatment and other patient characteristics, including the DAS28-CRP. RESULTS: Baseline hemoglobin was inversely associated with ΔSHS in adjusted analyses (P < 0.05 for both sexes). Baseline anemia predicted greater ΔSHS in MTX-treated patients over 104 weeks, and in ADA- and combination-treated patients over 26 weeks. Lower hemoglobin concentrations over time, as well as time with anemia, were associated with greater damage progression (P < 0.001). The effect of low hemoglobin concentrations on joint damage progression remained significant, even in patients achieving low disease activity. CONCLUSION: Low hemoglobin is a DAS28-CRP-independent predictor of radiographic joint damage progression in MTX-treated patients with early RA. This effect decreases over time in ADA- and combination-treated patients, and in clinical responders irrespective of treatment modality.
引用
- Möller B, Everts-Graber J, Florentinus S, et al. Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial. Arthritis Care Res (Hoboken). 2018. PMID: 28950430. doi:10.1002/acr.23427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。